Aprea Therapeutics, Inc.
APRE
$-0.10
Change (1 day)
$8.85
Year High
$2.15
Year Low
Categories
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
P/B ratio for Aprea Therapeutics, Inc. (APRE)
P/B ratio as of 2023: 0.93
According to Aprea Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.93. At the end of 2022 the company had a P/B ratio of 0.02.
P/B ratio history for Aprea Therapeutics, Inc. from 2017 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 0.93 |
| 2022 | 0.02 |
| 2021 | 1.23 |
| 2020 | 1.34 |
| 2019 | 2.22 |
| 2018 | -5.61 |
| 2017 | -8.07 |